CNTA News and Press, Centessa Pharmaceuticals plc From 02/08/24

2024-02-08 09:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-05 13:48:46 ET Summary Centessa Pharmaceuticals has a unique business model that combines the flexibility of small-scale biotechs with the support of a large corporation. The company has a strong pipeline of therapeutics addressing various conditions, with a focus on hemop...

BOSTON and LONDON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced its participation in the 42 nd Annual J.P. Morgan Healthcare...

Part 5 data reinforces favorable safety and tolerability profile and long-term efficacy results for SerpinPC: Median all-bleed ABR of 1.0, a 96% reduction from prospective baseline No thromboembolic events or treatment-related sustained elevations of D-dimer observed P...

2023-11-29 21:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Anaptys licenses exclusive global development and commercialization rights to a potential best-in-class BDCA2 modulator portfolio IND filing to support clinical development of ANB101 in autoimmune and inflammatory diseases expected in H2 2024 Reiterating year-end 2023 cash and investmen...

2023-11-15 14:36:07 ET More on Centessa Pharmaceuticals Centessa Pharmaceuticals: A Diversified Bet In Underserved Markets Morgan Stanley impressed with Centessa's lead candidate data at World Sleep Congress Seeking Alpha’s Quant Rating on Centessa Pharmaceuti...

2023-11-14 02:09:59 ET More on Centessa Pharmaceuticals Centessa Pharmaceuticals: A Diversified Bet In Underserved Markets Centessa Pharmaceuticals: Pipeline Progresses As PRESent-2 Initiated Morgan Stanley impressed with Centessa's lead candidate data at World Sleep...

SerpinPC: Ongoing registrational PRESent-2 and PRESent-3 studies for the treatment of hemophilia B; New data from ongoing Phase 2a study accepted for poster presentation at American Society of Hematology (ASH) Annual Meeting in December 2023 ORX750: Preclinical data suppor...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...